Clinical Trial

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to target underlying mechanisms that promote muscle fatigue in patients with breast cancer. This represents an off-label use of this compound, both in terms of the patient population and the clinical phenotype targeted. The central research hypothesis of this study is that daily pioglitazone will restore transcriptional downregulation of pathways within skeletal that promote fatigue.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-08-18; most recent amendment 2025-04-04.
Status change: Not Yet Recruiting → Recruiting 2021-12-01
Trial Details
NCT Number NCT05013255
Lead Sponsor West Virginia University
Conditions Breast Cancer, Muscle Fatigue
Enrollment 30 participants
Start Date 2021-12-23
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-08